Related references
Note: Only part of the references are listed.MonitoringCART-cells using flow cytometry
Julie Demaret et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2021)
Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
Elisabeth Laurent et al.
ACS SYNTHETIC BIOLOGY (2021)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
Alyssa Sheih et al.
NATURE COMMUNICATIONS (2020)
Getting CD19 Into Shape: Expression of Natively Folded Difficult-to- Express CD19 for Staining and Stimulation of CAR-T Cells
Elisabeth Lobner et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy
Wentao Li et al.
IMMUNITY (2020)
The Chimeric Antigen Receptor Detection Toolkit
Yifei Hu et al.
FRONTIERS IN IMMUNOLOGY (2020)
convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
Kyle E. Landgraf et al.
COMMUNICATIONS BIOLOGY (2020)
Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides
Preeti Sharma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner et al.
MOLECULAR THERAPY (2020)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Qing Deng et al.
NATURE MEDICINE (2020)
Engineering and Design of Chimeric Antigen Receptors
Sonia Guedan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
Michelle Seif et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
Judith Feucht et al.
NATURE MEDICINE (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
John Rossi et al.
BLOOD (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Chimeric antigen receptors that trigger phagocytosis
Meghan A. Morrissey et al.
ELIFE (2018)
Strategies to Address Chimeric Antigen Receptor Tonic Signaling
Adam Ajina et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR
Motoharu Hamada et al.
EBIOMEDICINE (2018)
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Alec J. Walker et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yinmeng Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
Mark O'Hara et al.
IMMUNOTHERAPY (2016)
Detection, phenotyping, and quantification of antigen-specific T cells using a peptide-MHC dodecamer
Jun Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
Satiro N. De Oliveira et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials
Bipulendu Jena et al.
PLOS ONE (2013)
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
Zhili Zheng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis
Mark M. Davis et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Tricks with tetramers: how to get the most from multimeric peptide-MHC
Linda Wooldridge et al.
IMMUNOLOGY (2009)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
The kinetic-segregation model: TCR triggering and beyond
Simon J. Davis et al.
NATURE IMMUNOLOGY (2006)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers
CL Day et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism
ES José et al.
IMMUNITY (2000)
Share Paper
